Genome-Based Cancer Treatment: A Q&A with Elaine Mardis

Self-professed tech geek Elaine Mardis aims to transform cancer diagnosis and treatment using genetic sequencing.

By Jeanne Erdmann
Jan 27, 2014 4:00 PMNov 12, 2019 4:53 AM
elaine-mardis.jpg
Elaine Mardis says the days of one-size-fits-all therapeutics will soon be gone. | Whitney Curtis

Newsletter

Sign up for our email newsletter for the latest science news
 

Elaine Mardis lives for dream machines, from her glossy red Audi S5 to the roomful of shiny new DNA sequencers housed at the Genome Institute at Washington University in St. Louis. As co-director of the institute and director of technology development, Mardis leads teams that are using genome science to transform the diagnosis and treatment of cancer.

A self-professed tech geek, Mardis has been a pioneer of the technological breakthroughs that made it possible to decrypt the 3 billion-plus A’s and T’s, G’s and C’s that make up the human genome. 

Since the 1990s, her team has often been the first to test-drive new sequencing machines. They sequenced the first whole animal, the flatworm, in 1998, and then pushed the systems to handle big chunks of bigger genomes — billions of base pairs. 

0 free articles left
Want More? Get unlimited access for as low as $1.99/month

Already a subscriber?

Register or Log In

0 free articlesSubscribe
Discover Magazine Logo
Want more?

Keep reading for as low as $1.99!

Subscribe

Already a subscriber?

Register or Log In

Stay Curious

Sign up for our weekly newsletter and unlock one more article for free.

 

View our Privacy Policy


Want more?
Keep reading for as low as $1.99!


Log In or Register

Already a subscriber?
Find my Subscription

More From Discover
Recommendations From Our Store
Shop Now
Stay Curious
Join
Our List

Sign up for our weekly science updates.

 
Subscribe
To The Magazine

Save up to 40% off the cover price when you subscribe to Discover magazine.

Copyright © 2024 Kalmbach Media Co.